Loading…
Loading…
CVS Health trades at a discounted 12x forward P/E versus peers, despite robust business momentum and integrated healthcare assets. Q2 2026 saw 7% YoY revenue growth to $106B and 35% adjusted operating income growth, signaling a turnaround in earnings power. Aetna margin restoration, specialty pharmacy growth, and GLP-1 expansion offset risks from elevated medical costs and regulatory headwinds.
CVS Health Corporation (CVS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
CVS Health NYSE: CVS executives said the company is seeing improved momentum across its insurance, pharmacy, care delivery and balance-sheet priorities, while maintaining a cautious outlook on healthcare cost trends and several 2027 headwinds.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
WOONSOCKET, R.I., Sept. 9, 2026 /PRNewswire/ -- New survey findings commissioned by CVS Health® (NYSE: CVS) reveal that many Americans face persistent barriers accessing preventive health screenings.
CVS Health has significantly improved its business since last year. The company is performing well financially as a result.
On Aug. 31, 2026, Richard Pzena (Trades, Portfolio)'s firm, Pzena Investment Management, significantly increased its stake in Globant SA (GLOB, Financial), acqu